Cargando…

Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity

Drug resistance is a major cause of the inefficacy of conventional cancer therapies, and often accompanied by severe side effects. Thus, there is an urgent need to develop novel drugs with low cytotoxicity, high selectivity and minimal acquired chemical resistance. Peptide-based drugs (less than 0.5...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdou, Youssef T., Saleeb, Sheri M., Abdel-Raouf, Khaled M. A., Allam, Mohamed, Adel, Mustafa, Amleh, Asma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369728/
https://www.ncbi.nlm.nih.gov/pubmed/37495988
http://dx.doi.org/10.1186/s12885-023-11045-4
_version_ 1785077820652781568
author Abdou, Youssef T.
Saleeb, Sheri M.
Abdel-Raouf, Khaled M. A.
Allam, Mohamed
Adel, Mustafa
Amleh, Asma
author_facet Abdou, Youssef T.
Saleeb, Sheri M.
Abdel-Raouf, Khaled M. A.
Allam, Mohamed
Adel, Mustafa
Amleh, Asma
author_sort Abdou, Youssef T.
collection PubMed
description Drug resistance is a major cause of the inefficacy of conventional cancer therapies, and often accompanied by severe side effects. Thus, there is an urgent need to develop novel drugs with low cytotoxicity, high selectivity and minimal acquired chemical resistance. Peptide-based drugs (less than 0.5 kDa) have emerged as a potential approach to address these issues due to their high specificity and potent anticancer activity. In this study, we developed a support vector machine model (SVM) to detect the potential anticancer properties of novel peptides by scanning the American University in Cairo (AUC) Red Sea metagenomics library. We identified a novel 37-mer antimicrobial peptide through SVM pipeline analysis and characterized its anticancer potential through in silico cross-examination. The peptide sequence was further modified to enhance its anticancer activity, analyzed for gene ontology, and subsequently synthesized. To evaluate the anticancer properties of the modified 37-mer peptide, we assessed its effect on the viability and morphology of SNU449, HepG2, SKOV3, and HeLa cells, using an MTT assay. Additionally, we evaluated the migration capabilities of SNU449 and SKOV3 cells using a scratch-wound healing assay. The targeted selectivity of the modified peptide was examined by evaluating its hemolytic activity on human erythrocytes. Treatment with the peptide significantly reduced cell viability and had a critical impact on the morphology of hepatocellular carcinoma (SNU449 and HepG2), and ovarian cancer (SKOV3) cells, with a marginal effect on cervical cancer cell lines (HeLa). The viability of a human fibroblast cell line (1Br-hTERT) was also significantly reduced by peptide treatment, as were the proliferation and migration abilities of SNU449 and SKOV3 cells. The annexin V assay revealed programmed cell death (apoptosis) as one of the potential cellular death pathways in SNU449 cells upon peptide treatment. Finally, the peptide exhibited antimicrobial effects on both gram-positive and gram-negative bacterial strains. The findings presented here suggest the potential of our novel peptide as a potent anticancer and antimicrobial agent. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11045-4.
format Online
Article
Text
id pubmed-10369728
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103697282023-07-27 Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity Abdou, Youssef T. Saleeb, Sheri M. Abdel-Raouf, Khaled M. A. Allam, Mohamed Adel, Mustafa Amleh, Asma BMC Cancer Research Drug resistance is a major cause of the inefficacy of conventional cancer therapies, and often accompanied by severe side effects. Thus, there is an urgent need to develop novel drugs with low cytotoxicity, high selectivity and minimal acquired chemical resistance. Peptide-based drugs (less than 0.5 kDa) have emerged as a potential approach to address these issues due to their high specificity and potent anticancer activity. In this study, we developed a support vector machine model (SVM) to detect the potential anticancer properties of novel peptides by scanning the American University in Cairo (AUC) Red Sea metagenomics library. We identified a novel 37-mer antimicrobial peptide through SVM pipeline analysis and characterized its anticancer potential through in silico cross-examination. The peptide sequence was further modified to enhance its anticancer activity, analyzed for gene ontology, and subsequently synthesized. To evaluate the anticancer properties of the modified 37-mer peptide, we assessed its effect on the viability and morphology of SNU449, HepG2, SKOV3, and HeLa cells, using an MTT assay. Additionally, we evaluated the migration capabilities of SNU449 and SKOV3 cells using a scratch-wound healing assay. The targeted selectivity of the modified peptide was examined by evaluating its hemolytic activity on human erythrocytes. Treatment with the peptide significantly reduced cell viability and had a critical impact on the morphology of hepatocellular carcinoma (SNU449 and HepG2), and ovarian cancer (SKOV3) cells, with a marginal effect on cervical cancer cell lines (HeLa). The viability of a human fibroblast cell line (1Br-hTERT) was also significantly reduced by peptide treatment, as were the proliferation and migration abilities of SNU449 and SKOV3 cells. The annexin V assay revealed programmed cell death (apoptosis) as one of the potential cellular death pathways in SNU449 cells upon peptide treatment. Finally, the peptide exhibited antimicrobial effects on both gram-positive and gram-negative bacterial strains. The findings presented here suggest the potential of our novel peptide as a potent anticancer and antimicrobial agent. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11045-4. BioMed Central 2023-07-26 /pmc/articles/PMC10369728/ /pubmed/37495988 http://dx.doi.org/10.1186/s12885-023-11045-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Abdou, Youssef T.
Saleeb, Sheri M.
Abdel-Raouf, Khaled M. A.
Allam, Mohamed
Adel, Mustafa
Amleh, Asma
Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity
title Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity
title_full Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity
title_fullStr Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity
title_full_unstemmed Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity
title_short Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity
title_sort characterization of a novel peptide mined from the red sea brine pools and modified to enhance its anticancer activity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369728/
https://www.ncbi.nlm.nih.gov/pubmed/37495988
http://dx.doi.org/10.1186/s12885-023-11045-4
work_keys_str_mv AT abdouyousseft characterizationofanovelpeptideminedfromtheredseabrinepoolsandmodifiedtoenhanceitsanticanceractivity
AT saleebsherim characterizationofanovelpeptideminedfromtheredseabrinepoolsandmodifiedtoenhanceitsanticanceractivity
AT abdelraoufkhaledma characterizationofanovelpeptideminedfromtheredseabrinepoolsandmodifiedtoenhanceitsanticanceractivity
AT allammohamed characterizationofanovelpeptideminedfromtheredseabrinepoolsandmodifiedtoenhanceitsanticanceractivity
AT adelmustafa characterizationofanovelpeptideminedfromtheredseabrinepoolsandmodifiedtoenhanceitsanticanceractivity
AT amlehasma characterizationofanovelpeptideminedfromtheredseabrinepoolsandmodifiedtoenhanceitsanticanceractivity